Chemomab Therapeutics Ltd ADR (CMMB)

$1.02 -0.03 (-2.86%)
Market Cap 14.93M
Revenue (ttm) 0.00
Net Income (ttm) -13.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 133,412
Avg Vol 426,626
Day's Range N/A - N/A
Shares Out 14.36M
Stochastic %K 35%
Beta 0.66
Analysts Strong Sell
Price Target $9.00

Latest News on CMMB

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Mar 27, 2025, 3:18 PM EDT - 11 days ago

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Mar 27, 2025, 8:30 AM EDT - 11 days ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Mar 6, 2025, 8:00 AM EST - 4 weeks ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Mar 3, 2025, 8:00 AM EST - 5 weeks ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Feb 19, 2025, 7:00 AM EST - 6 weeks ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Dec 3, 2024, 7:00 AM EST - 4 months ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Nov 19, 2024, 7:00 AM EST - 4 months ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 21, 2024, 7:00 AM EDT - 8 months ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Aug 12, 2024, 7:00 AM EDT - 8 months ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 30, 2024, 9:00 AM EDT - 8 months ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 26, 2024, 7:00 AM EDT - 9 months ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:38 AM EDT - 9 months ago

Chemomab Therapeutics Announces $10 Million Private Placement

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jul 25, 2024, 7:00 AM EDT - 9 months ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

Jun 6, 2024, 7:00 AM EDT - 10 months ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 17, 2024, 7:00 AM EDT - 11 months ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 11 months ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 8, 2024, 7:00 AM EDT - 11 months ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

May 2, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 25, 2024, 7:06 AM EDT - 1 year ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 7, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Mar 5, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 20, 2024, 7:00 AM EST - 1 year ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 14, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Feb 5, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 30, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Jan 3, 2024, 7:00 AM EST - 1 year ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 16, 2023, 7:00 AM EST - 1 year ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 15, 2023, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Nov 13, 2023, 8:00 AM EST - 1 year ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Nov 6, 2023, 4:15 PM EST - 1 year ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Oct 30, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Oct 26, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

Sep 28, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 29, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

Aug 14, 2023, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

Jun 28, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

Jun 26, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023

Jun 21, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

Jun 5, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

Jun 2, 2023, 9:00 AM EDT - 2 years ago

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

May 14, 2023, 11:20 AM EDT - 2 years ago

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

May 11, 2023, 6:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update

Apr 12, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update

Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023

Mar 29, 2023, 8:30 AM EDT - 2 years ago

Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update

Mar 17, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update